详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL).

10| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei Province, China. [2]Department of Chemistry, Temple University, Philadelphia, Pennsylvania 19087, USA. [3]School of Basic Medical Sciences, Hebei University of Chinese Medicine, Shijiazhuang, 050200 Hebei Province, China. [4]Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei Province, China. [5]Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang 050011, China.

出处：

DOI：

ISSN：

摘要：

At present, the use of the common chemotherapy regimen CHOP/R-CHOP for diffuse large B-cell lymphoma (DLBCL) has some shortcomings, especially for relapsed and refractory DLBCL. CD47 is now considered as a prominent target in cancer therapies, and CD47 blockade mainly inhibits the CD47-SIRPα axis to prevent tumor immune escape. Here, we evaluated the effects of the latest CD47 antibodies reported and the correlations of closely related genes with CD47 in this disease. In the future, therapeutic strategies for DLBCL will focus on multitarget antibody combined treatment and multigene joint attacks.Copyright © 2021 Wenqi Zhang et al.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 3 区生物工程与应用微生物 3 区遗传学 3 区病理学 4 区医学：研究与实验

最新[2025]版：

无

JCR分区：

出版当年[2021]版：

Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q2 GENETICS & HEREDITY Q2 PATHOLOGY Q3 MEDICINE, RESEARCH & EXPERIMENTAL

最新[2023]版：

无

影响因子： 0 最新[2023版] 0 最新五年平均 3.464 出版当年[2021版] 3.697 出版当年五年平均 3.434 出版前一年[2020版]

第一作者：

第一作者机构： [1]Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei Province, China.

通讯作者：

通讯机构： [1]Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei Province, China. [5]Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang 050011, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：